Management of Recurrent Scalp Dermatitis Resistant to Topical Treatment in Children

Introduction to Treatment Options

The American Academy of Dermatology recommends wet-wrap therapy with topical corticosteroids as an effective and relatively safe short-term second-line treatment option for children with recurrent scalp dermatitis resistant to topical treatments 1
The use of low to medium potency topical corticosteroids (TCSs) is recommended as the first-line treatment for inflammatory skin conditions, ensuring proper use 1
Regular use of emollients has both short and long-term steroid-sparing effects in mild to moderate dermatitis 1

For facial and intertriginous areas, topical calcineurin inhibitors (TCIs) are preferred to avoid skin atrophy, as suggested by the American Academy of Dermatology 2
Wet-wrap therapy with TCSs serves as an effective barrier against scratching, promotes trans-epidermal penetration of TCSs, and is recommended for 3-7 days, with possible extension to 14 days in severe cases 1
Tacrolimus ointment 0.03% and pimecrolimus cream 1% are recommended for children aged 2 years and above, particularly useful for steroid-resistant cases and as steroid-sparing agents 1, 2

For seborrheic dermatitis of the scalp, low-potency topical corticosteroids are recommended for short-term control (less than 7 days) 2
For atopic dermatitis of the scalp, a combination of calcipotriol/betamethasone dipropionate suspension applied once daily for up to 8 weeks may be effective for children 12 years and older, as suggested by the American Academy of Dermatology 3

Infants and young children should be treated with less potent TCSs due to increased risk of adrenal suppression 1
Long-term application of topical antibiotics is not recommended due to increased risk of resistance and sensitization 1
Consider bacterial infection if there is poor response to treatment; use systemic antibiotics only when there is clinical evidence of infection 1, 5
If using calcipotriene/calcipotriol on large body surface areas, monitor vitamin D metabolites, as recommended by the American Academy of Dermatology 3
Consider poor treatment adherence if response is inadequate 5
Evaluate for other diagnoses if treatment response remains poor despite appropriate therapy 5